FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890572331> ?p ?o ?g. }

• W2890572331 abstract "8033 Background: Daratumumab (D) plus lenalidomide and dexamethasone (Rd; POLLUX) or with bortezomib and dexamethasone (Vd; CASTOR) demonstrated prolonged PFS and tolerability compared with Rd and Vd alone, respectively, in RRMM pts. We examined the safety and efficacy profiles of DRd and DVd in elderly (≥75 y) pts from these phase 3 studies. Methods: Pts with ≥1 prior line of therapy were enrolled. All pts in POLLUX were treated until progression; CASTOR pts received 8 cycles of Vd ± daratumumab. Different D (16 mg/kg) dosing schedules were used in POLLUX (qw for cycles 1-2, q2w for cycles 3-6, and q4w thereafter) and CASTOR (qw in Cycles 1-3, q3w for Cycles 4-8, and q4w thereafter). Elderly pts received a reduced dexamethasone dose (20 mg once weekly). Results: In POLLUX, 29/286 (DRd) and 35/283 (Rd) were ≥75 y, with 86% and 91% having ECOG status ≤1, respectively. With 17.3 months of median follow up, 10% in DRd and 11% in Rd discontinued due to treatment-emergent adverse events (TEAEs). Common (>10%) grade 3/4 TEAEs for DRd included neutropenia and hypokalemia (Table). Twelve (41%) DRd pts experienced infusion-related reactions (IRR) and 4 (14%) experienced grade 3/4 IRR; none discontinued due to IRR. Median PFS was not reached (NR) in DRd vs 11.4 months in Rd (HR 0.19; 95% CI, 0.06-0.55; P=0.0007), and ≥CR % was significantly higher with DRd vs Rd (52% vs 9%; P=0.0002). In CASTOR, 23/251 (DVd) and 35/247 (Vd) were ≥75 y, with 100% and 94% having ECOG status ≤1, respectively. With 13.0 months of median follow up, rates of discontinuation due to TEAEs were similar (15% vs 20%). Thrombocytopenia, fatigue, and pneumonia were common grade 3/4 TEAEs for DVd (Table). Thirteen (65%) pts reported IRR (10% grade 3/4) and no pts discontinued due to IRR. Median PFS was NR in DVd vs 8.1 months in Vd (HR 0.27; 95% CI, 0.12-0.61; P=0.0007), and significantly higher ≥CR % was observed in DVd vs Vd (25% vs 3%; P=0.0154). Conclusions: The safety and efficacy profiles in elderly pts were generally comparable with the overall population in each study. Clinical trial information: NCT02136134 and NCT02076009. [Table: see text]" @default.
• W2890572331 created "2018-09-27" @default.
• W2890572331 creator A5002073335 @default.
• W2890572331 creator A5009378735 @default.
• W2890572331 creator A5012247336 @default.
• W2890572331 creator A5012405296 @default.
• W2890572331 creator A5015892119 @default.
• W2890572331 creator A5022520524 @default.
• W2890572331 creator A5022522496 @default.
• W2890572331 creator A5027919726 @default.
• W2890572331 creator A5029159537 @default.
• W2890572331 creator A5038580329 @default.
• W2890572331 creator A5049711954 @default.
• W2890572331 creator A5065238694 @default.
• W2890572331 creator A5065915270 @default.
• W2890572331 creator A5070014603 @default.
• W2890572331 creator A5071926851 @default.
• W2890572331 creator A5078852881 @default.
• W2890572331 creator A5084124427 @default.
• W2890572331 creator A5086005303 @default.
• W2890572331 creator A5086077649 @default.
• W2890572331 date "2017-05-20" @default.
• W2890572331 modified "2023-10-17" @default.
• W2890572331 title "Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR." @default.
• W2890572331 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.8033" @default.
• W2890572331 hasPublicationYear "2017" @default.
• W2890572331 type Work @default.
• W2890572331 sameAs 2890572331 @default.
• W2890572331 citedByCount "3" @default.
• W2890572331 countsByYear W28905723312017 @default.
• W2890572331 countsByYear W28905723312018 @default.
• W2890572331 crossrefType "journal-article" @default.
• W2890572331 hasAuthorship W2890572331A5002073335 @default.
• W2890572331 hasAuthorship W2890572331A5009378735 @default.
• W2890572331 hasAuthorship W2890572331A5012247336 @default.
• W2890572331 hasAuthorship W2890572331A5012405296 @default.
• W2890572331 hasAuthorship W2890572331A5015892119 @default.
• W2890572331 hasAuthorship W2890572331A5022520524 @default.
• W2890572331 hasAuthorship W2890572331A5022522496 @default.
• W2890572331 hasAuthorship W2890572331A5027919726 @default.
• W2890572331 hasAuthorship W2890572331A5029159537 @default.
• W2890572331 hasAuthorship W2890572331A5038580329 @default.
• W2890572331 hasAuthorship W2890572331A5049711954 @default.
• W2890572331 hasAuthorship W2890572331A5065238694 @default.
• W2890572331 hasAuthorship W2890572331A5065915270 @default.
• W2890572331 hasAuthorship W2890572331A5070014603 @default.
• W2890572331 hasAuthorship W2890572331A5071926851 @default.
• W2890572331 hasAuthorship W2890572331A5078852881 @default.
• W2890572331 hasAuthorship W2890572331A5084124427 @default.
• W2890572331 hasAuthorship W2890572331A5086005303 @default.
• W2890572331 hasAuthorship W2890572331A5086077649 @default.
• W2890572331 hasConcept C121332964 @default.
• W2890572331 hasConcept C126322002 @default.
• W2890572331 hasConcept C142424586 @default.
• W2890572331 hasConcept C143998085 @default.
• W2890572331 hasConcept C187960798 @default.
• W2890572331 hasConcept C2776063141 @default.
• W2890572331 hasConcept C2776364478 @default.
• W2890572331 hasConcept C2781119759 @default.
• W2890572331 hasConcept C44249647 @default.
• W2890572331 hasConcept C71924100 @default.
• W2890572331 hasConcept C87355193 @default.
• W2890572331 hasConceptScore W2890572331C121332964 @default.
• W2890572331 hasConceptScore W2890572331C126322002 @default.
• W2890572331 hasConceptScore W2890572331C142424586 @default.
• W2890572331 hasConceptScore W2890572331C143998085 @default.
• W2890572331 hasConceptScore W2890572331C187960798 @default.
• W2890572331 hasConceptScore W2890572331C2776063141 @default.
• W2890572331 hasConceptScore W2890572331C2776364478 @default.
• W2890572331 hasConceptScore W2890572331C2781119759 @default.
• W2890572331 hasConceptScore W2890572331C44249647 @default.
• W2890572331 hasConceptScore W2890572331C71924100 @default.
• W2890572331 hasConceptScore W2890572331C87355193 @default.
• W2890572331 hasLocation W28905723311 @default.
• W2890572331 hasOpenAccess W2890572331 @default.
• W2890572331 hasPrimaryLocation W28905723311 @default.
• W2890572331 hasRelatedWork W2285291701 @default.
• W2890572331 hasRelatedWork W2588447548 @default.
• W2890572331 hasRelatedWork W2761237722 @default.
• W2890572331 hasRelatedWork W2777372025 @default.
• W2890572331 hasRelatedWork W2889564833 @default.
• W2890572331 hasRelatedWork W2890158438 @default.
• W2890572331 hasRelatedWork W2890326711 @default.
• W2890572331 hasRelatedWork W2890977830 @default.
• W2890572331 hasRelatedWork W2949734536 @default.
• W2890572331 hasRelatedWork W2952813810 @default.
• W2890572331 hasRelatedWork W2955655006 @default.
• W2890572331 hasRelatedWork W2978510275 @default.
• W2890572331 hasRelatedWork W2996272948 @default.
• W2890572331 hasRelatedWork W3128345370 @default.
• W2890572331 hasRelatedWork W3132592784 @default.
• W2890572331 hasRelatedWork W3154178689 @default.
• W2890572331 hasRelatedWork W3164760476 @default.
• W2890572331 hasRelatedWork W3171552343 @default.
• W2890572331 hasRelatedWork W3180430919 @default.
• W2890572331 hasRelatedWork W3204897460 @default.
• W2890572331 isParatext "false" @default.
• W2890572331 isRetracted "false" @default.
• W2890572331 magId "2890572331" @default.
• W2890572331 workType "article" @default.